Current state of castration-resistant prostate cancer

American Journal of Managed Care

Volumn 19, Issue 18 SUPPL., 2013, Pages

  Petrylak, Daniel P ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GROWTH FACTOR; ANTIANDROGEN;

ARTICLE; BONE METASTASIS; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; MALE; OSTEOBLAST; PRIORITY JOURNAL; PROSTATE CANCER; AGED; CANCER STAGING; DISEASE COURSE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK ASSESSMENT; SURVIVAL; TUMOR INVASION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 84904390889     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. CA Cancer J Clin. 2013;63:11-30.
2. Prostate Cancer Treatment. National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/treatment/prostate/patient.
3. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19(2):175-181. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064270/. Accessed October 2013.
4. Prostate Cancer, V.4.2013. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. http://www.nccn.org/professionals/physician- gls/pdf/prostate.pdf.
5. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591-1597. (Pubitemid 29211767)
6. Ryan CJ, Small EJ. High risk biochemical relapse and the timing of androgen deprivation therapy. J Urol. 2006;176(6, pt 2):S61-S65. (Pubitemid 44648138)
7. National Cancer Institute. Prostate Cancer Treatment (PDQ®). http://www.cancer.gov/cancertopics/pdq/treatment/prostate/HealthProfessional/ page1/AllPages#Section-47.
8. Moul J, Armstrong AJ, Lattanzi J. Prostate cancer. 2013;8. http://www.cancernetwork.com/cancer-management/prostate/article/10165/1802626? pageNumber=5.
9. Chi KN, Bjartell A, Dearnaley D, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol. 2009;56:594-605.
10. Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol. 2011;29:3695- 3704.
11. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Eng J Med. 2004;351:1488-1490. (Pubitemid 39315314)
12. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34-45. (Pubitemid 33741879)
13. Velcheti V, Karnik S, Bardot SF, Prakash O. Pathogenesis of prostate cancer: lessons from basic research. Ochsner J. 2008; 8:213-218.
14. Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression [published online August 23, 2011]. J Carcinog. 2011;10:20. doi:10.4103/1477-3163 .83937.
15. Henshall SM, Quinn DM, Lee CS, et al. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res. 2001;61:423-427. (Pubitemid 32128590)
16. Ricciardelli C, Choong CS, Buchanan G, et al. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate. 2005; 63:19-28. (Pubitemid 40365387)
17. Scher HI, Buchanan G, Gerald W, et al. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer. 2004;11:459-476. (Pubitemid 39331277)
18. Nacusi LP, Tindall DJ. Androgen receptor abnormalities in castration-recurrent prostate cancer. Expert Rev Endocrinol Metab. 2009;5:417-422.
19. Buchanan G, Irvine RA, Coetzee GA, et al. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev. 2001;20:207-223. (Pubitemid 34595269)
20. Steinkamp MP, O'Mahony OA, Brogley M, et al. Treatmentdependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res. 2009;69: 4434-4442.
21. Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008;68:6407-6415.
22. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev. 2007;28:778-808. (Pubitemid 350294296)
23. Zhu ML, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer. 2008;15:841-849.
24. Bergerat JP, Céraline J. Pleiotropic functional properties of androgen receptor mutants in prostate cancer. Hum Mutat. 2009; 30:145-157.
25. Shiota M, Yokomizo A, Naito S, et al. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer. Free Radic Biol Med. 2011;51:1320-1328.
26. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33-39. (Pubitemid 38524696)
27. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995;9:401-406.
28. Scher HI, Sawyers CL. Biology of progressive, castrationresistant prostate cancer: directed therapies targeting the androgen- receptor signaling axis. J Clin Oncol. 2005;23:8253-8261. (Pubitemid 46211563)
29. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res. 2009;15:3251-3255.
30. Shiota M, Yokomizo A, Fujimoto N, Naito S. Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer. Curr Cancer Drug Targets. 2011;11:870-881.
31. Cunha TR, Donjacour AA. Mesenchymal-epithelial interactions in the growth and development of the prostate. Cancer Treat Res. 1989;46:159-175.
32. Byrne RL, Leung H, Neal DE. Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Br J Urol. 1996;77:627-633. (Pubitemid 27402266)
33. Culig Z, Steiner H, Bartshc G, Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem. 2005;95:497-505. (Pubitemid 41420180)
34. Nakashima J, Tachibana M, Horiguchi Y, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res. 2000;6:2702-2706. (Pubitemid 30482107)
35. Wang Y, Romigh T, He X, et al. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines. Hum Mol Genet. 2010;19:4319-4329.
36. Mohler JL. Castration-recurrent prostate cancer is not androgen- independent. Adv Exp Med Biol. 2008;617:223-224.
37. Geller J. Basis for hormonal management of advanced prostate cancer. Cancer. 1993;71(3 suppl):1039-1045. (Pubitemid 23049629)
38. Geller J, Liu J, Albert J, et al. Relationship between human prostatic epithelial cell protein synthesis and tissue dihydrotestosterone level. Clin Endocrinol (Oxf). 1987;26:155-161. (Pubitemid 17015701)
39. Peskin SR. Immunotherapy for advanced prostate cancer: a novel treatment option to improve survival. Managed Care. 2011;20(suppl 5):1-11.
40. Vieweg J. Immunotherapy for prostate cancer. Rev Urol. 2007;9:S29-S38.
41. Drake CG. Prostate cancer as a model for tumor immunotherapy. Nature Rev Immunol. 2010;10:580-593.
42. Sowery RD, So AL, Gleave ME. Therapeutic options in advanced prostate cancer: present and future. Curr Urol Rep. 2007;8:53-59. (Pubitemid 46202659)
43. Shapiro D, Tareen B. Current and emerging treatments in the management of castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2012;12:951-964.
44. Stenze A. RANK Ligand: a key role in cancer-induced bone destruction? Eur Urol. 2009(suppl 8)823-838.
45. O'Donnell P. Metastatic cancer of bone. http://www.orthobullets.com/ pathology/8045/metastatic-cancer-of-bone.
46. Mehra R, Kumar-Sinha C, Shankar S, et al. Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res. 2011;17:3924-3932.
47. G, Sircar K, Aprikian A, et al. Expression of RANKL/RANK/ OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer. 2006; 107:289-298.
48. Armstrong AJ, Eisenberger MA, Halabi S, et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol. 2012;61:549-559.
49. Martin NE, Mucci LA, Loda M, DePinho RA. Prognostic determinants in prostate cancer. Cancer J. 2011;17:429-437.
50. Penney KL Sinnott JA, Fall K, et al. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011;29:2391-2396.
51. Bitting RL, Armstrong AJ. Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer. Cancer J. 2013;19:25-33.
52. Cookson MS, Roth BJ, Dahm P et al. Castration-Resistant Prostate Cancer: AUA Guideline [published online May 9, 2013]. J Urol. pii:S0022-5347(13)04327-9. doi:10.1016/j.juro.2013.05.005.